Business Focus
Clinical Focus
Spotlight
100 Years
CME/CE
Job Board
- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
Adding saxagliptin to metformin results in better glycemic control vs. uptitrating metformin dose
Adding saxagliptin to metformin instead of increasing the dose of metformin results in significant improvement in levels of hemoglobin 1c (HbA1c), fasting plasma glucose, and postprandial glucose in patients with type 2 diabetes with inadequate glycemic control despite being on a stable dose of metformin, according to the results of a randomized open-label study.
Related Content
